Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.
3.

Bisphenol A and nonylphenol have the potential to stimulate the migration of ovarian cancer cells by inducing epithelial-mesenchymal transition via an estrogen receptor dependent pathway.

Kim YS, Hwang KA, Hyun SH, Nam KH, Lee CK, Choi KC.

Chem Res Toxicol. 2015 Apr 20;28(4):662-71. doi: 10.1021/tx500443p. Epub 2015 Mar 3.

PMID:
25690688
4.

Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways.

Hwang KA, Park MA, Kang NH, Yi BR, Hyun SH, Jeung EB, Choi KC.

Toxicol Appl Pharmacol. 2013 Nov 1;272(3):637-46. doi: 10.1016/j.taap.2013.07.027. Epub 2013 Aug 8.

PMID:
23933164
5.
6.
7.
8.

Benzophenone-1 stimulated the growth of BG-1 ovarian cancer cells by cell cycle regulation via an estrogen receptor alpha-mediated signaling pathway in cellular and xenograft mouse models.

Park MA, Hwang KA, Lee HR, Yi BR, Jeung EB, Choi KC.

Toxicology. 2013 Mar 8;305:41-8. doi: 10.1016/j.tox.2012.12.021. Epub 2013 Jan 14.

PMID:
23328252
9.

Genistein, a soy phytoestrogen, prevents the growth of BG-1 ovarian cancer cells induced by 17β-estradiol or bisphenol A via the inhibition of cell cycle progression.

Hwang KA, Kang NH, Yi BR, Lee HR, Park MA, Choi KC.

Int J Oncol. 2013 Feb;42(2):733-40. doi: 10.3892/ijo.2012.1719. Epub 2012 Nov 29.

PMID:
23229410
10.

The estrogen receptor signaling pathway activated by phthalates is linked with transforming growth factor-β in the progression of LNCaP prostate cancer models.

Lee HR, Hwang KA, Choi KC.

Int J Oncol. 2014 Aug;45(2):595-602. doi: 10.3892/ijo.2014.2460. Epub 2014 May 22.

PMID:
24858230
12.

Induced growth of BG-1 ovarian cancer cells by 17β-estradiol or various endocrine disrupting chemicals was reversed by resveratrol via downregulation of cell cycle progression.

Kang NH, Hwang KA, Kim TH, Hyun SH, Jeung EB, Choi KC.

Mol Med Rep. 2012 Jul;6(1):151-6. doi: 10.3892/mmr.2012.887. Epub 2012 Apr 23.

PMID:
22552626
13.
15.

The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer.

Yamamura S, Matsumura N, Mandai M, Huang Z, Oura T, Baba T, Hamanishi J, Yamaguchi K, Kang HS, Okamoto T, Abiko K, Mori S, Murphy SK, Konishi I.

Int J Cancer. 2012 Jan 1;130(1):20-8. doi: 10.1002/ijc.25961. Epub 2011 Apr 18.

16.
17.
18.

Egr1 is rapidly and transiently induced by estrogen and bisphenol A via activation of nuclear estrogen receptor-dependent ERK1/2 pathway in the uterus.

Kim HR, Kim YS, Yoon JA, Lyu SW, Shin H, Lim HJ, Hong SH, Lee DR, Song H.

Reprod Toxicol. 2014 Dec;50:60-7. doi: 10.1016/j.reprotox.2014.10.010. Epub 2014 Oct 18.

PMID:
25461906
19.

Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines.

Hu W, Wu W, Nash MA, Freedman RS, Kavanagh JJ, Verschraegen CF.

Anticancer Res. 2000 Mar-Apr;20(2A):729-33.

PMID:
10810347
Items per page

Supplemental Content

Write to the Help Desk